Q1 Earnings Estimate for BBIO Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for BridgeBio Pharma in a report released on Monday, February 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($0.73) for the quarter. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q2 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.85 EPS.

Other analysts have also recently issued reports about the company. Bank of America boosted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. HC Wainwright restated a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Cantor Fitzgerald restated an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. Finally, Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $51.67.

Remove Ads

BridgeBio Pharma Trading Up 1.9 %

BridgeBio Pharma stock traded up $0.65 during midday trading on Wednesday, reaching $34.90. The company's stock had a trading volume of 2,514,463 shares, compared to its average volume of 3,173,266. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $39.47. The business has a 50-day moving average price of $32.68 and a 200-day moving average price of $28.29. The stock has a market cap of $6.64 billion, a PE ratio of -12.25 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently modified their holdings of BBIO. Creative Planning acquired a new position in shares of BridgeBio Pharma during the third quarter worth approximately $772,000. Allspring Global Investments Holdings LLC raised its position in shares of BridgeBio Pharma by 17.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock worth $135,000 after purchasing an additional 801 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BridgeBio Pharma by 21.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company's stock worth $170,000 after purchasing an additional 1,214 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of BridgeBio Pharma by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 36,165 shares of the company's stock worth $921,000 after purchasing an additional 14,181 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of BridgeBio Pharma by 50.8% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company's stock worth $19,129,000 after purchasing an additional 253,101 shares during the period. 99.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 68,000 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the transaction, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at $3,402,477.82. This represents a 42.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil Kumar sold 326,932 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28. Following the transaction, the chief executive officer now directly owns 5,371,515 shares in the company, valued at $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,579,739 shares of company stock valued at $125,411,901. 24.66% of the stock is currently owned by company insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.